Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 1 Tag 23 Stunden
@MorphoSys
Relapsed or refractory diffuse large B-cell lymphoma (#DLBCL) affects thousands of adults every year. We are commit… https://t.co/jr9F9AvAMD
vor 4 Tage 23 Stunden
@MorphoSys
We are proud to have signed MassBio's Open Letter 2.0 - The CEO Pledge for a More Equitable & Inclusive Life Scienc… https://t.co/TI1ySoczJs
vor 5 Tage 20 Stunden
@MorphoSys
Today’s #worldpatientsafetyday focuses on the safety of health care workers globally as they face huge challenges a… https://t.co/r5JQ66YZNc
vor 1 Woche 15 Stunden
@MorphoSys
Today is #worldlymphomaday and buildings around the world are "lighting it red." We at MorphoSys stand united with… https://t.co/2IswokRzG3
vor 1 Woche 6 Tage
@MorphoSys
MorphoSys is deeply committed to supporting the blood cancer community. As #BloodCancerAwarenessMonth begins, we ar… https://t.co/UcYsEqtUhW
vor 1 Monat 4 Tage
@MorphoSys
The @NCCN added our FDA approved therapy, co-marketed with @Incyte, for adult patients in the U.S. with relapsed or… https://t.co/0URbZRUHym
vor 1 Monat 2 Wochen
@MorphoSys
We recently announced the approval of a new breakthrough designated therapy that addresses unmet needs of adult pat… https://t.co/y9tpg9MUfx
vor 1 Monat 2 Wochen
@MorphoSys
In partnership with @Incyte, we're proud to bring a new treatment option to adult patients with relapsed or refract… https://t.co/4nCAAb1u4b
vor 1 Monat 3 Wochen
@MorphoSys
Together with @Incyte, we've announced that the @US_FDA has approved a new targeted treatment for adult patients wi… https://t.co/ponPULCrkw
vor 3 Monate 1 Woche
@MorphoSys
Excited to participate in our second virtual conference, #EHA25Virtual, and to share new data on one of our investi… https://t.co/j0mCrLny1j
Investorenkontakt
Dr. Anja Pomrehn
Senior Vice President Head of Investor Relations
Telefon +49 89 89927 26972
Dr. Julia Neugebauer
Director Investor Relations
Telefon +49 89 89927 179
Medienkontakt
Sophie Petersen
Senior Specialist Corporate Communications
Telefon +49 89 89927 26033
Fax: +49 89 89927 526033